Daraxonrasib demonstrates initial antitumor activity in RAS-mutant lung cancer

Daraxonrasib, an oral RAS inhibitor therapy, achieved durable responses in pretreated patients with RAS-mutant non-small cell lung cancer in a Phase 1/2 trial. The study was led by David Hong, M.D., deputy chair of Investigational Cancer Therapeutics.

“Immunotherapy has improved outcomes for many patients with non-small cell lung cancer, but the majority of these cancers eventually progress,” Hong said. “At that point, the few treatment options available to these patients often have modest clinical benefit and substantial toxicities, so these early results are encouraging.”